First Horizon Advisors Inc. Purchases 60 Shares of Humana Inc. (NYSE:HUM)

First Horizon Advisors Inc. lifted its position in Humana Inc. (NYSE:HUM) by 11.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 581 shares of the insurance provider’s stock after purchasing an additional 60 shares during the quarter. First Horizon Advisors Inc.’s holdings in Humana were worth $148,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Pinnacle Wealth Management Advisory Group LLC increased its stake in Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock worth $272,000 after acquiring an additional 37 shares during the last quarter. Atlas Brown Inc. grew its holdings in shares of Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after purchasing an additional 38 shares in the last quarter. Moors & Cabot Inc. increased its position in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares during the last quarter. Mather Group LLC. raised its stake in Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after purchasing an additional 41 shares in the last quarter. Finally, Your Advocates Ltd. LLP lifted its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $255.06 on Thursday. The stock has a market capitalization of $30.77 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.05 and a beta of 0.56. The firm’s 50-day moving average price is $270.12 and its two-hundred day moving average price is $288.06. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.39%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

HUM has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and increased their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. TD Cowen upped their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Nineteen research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.